PRODUCT TYPES – Page 30

Biosimilar stability comparability failure after manufacturing site change: inspection-ready evidence pack for comparability and lifecycle management

The detection of biosimilar stability comparability failure often starts with specific symptoms observed on the manufacturing floor or in the laboratory. Key signals may include:Click to read the full article.

Transport time excursion during inspection readiness: patient safety assessment

Identifying symptoms that indicate a transport time excursion is the first step towards effective investigation. Key observations include:Click to read the full article.

Biosimilar stability comparability failure during biosimilar development: how to build a defensible similarity narrative with data integrity controls

Identifying the symptoms or signals associated with a stability comparability failure is the first step in mitigating risks. Common indicators may include:Click to read the full article.

Half-life deviation during transport to clinic: regulatory deviation handling

Symptoms of half-life deviations can manifest in various ways, which should be promptly identified and documented. Key signals include:Click to read the full article.

Biosimilar lot-to-lot variability trend (OOT) during analytical similarity assessment: decision tree for lab method variability vs true product differences

Symptoms of biosimilar lot-to-lot variability typically manifest as unexpected results during analytical similarity assessments. These may include:Click to read the full article.

Transport time excursion during transport to clinic: CAPA under time-critical constraints

Symptoms of transport time excursions may manifest in several ways. Key indicators include:Click to read the full article.

Biosimilar reference standard qualification gap during analytical similarity assessment: decision tree for lab method variability vs true product differences

Identifying signals indicative of a qualification gap during an analytical similarity assessment is critical for timely corrective action. Common symptoms that might suggest a deviation include:Click to read the full…

Radiochemical purity OOS during inspection readiness: regulatory deviation handling

Identifying symptoms related to radiochemical purity OOS is crucial in the early detection of deviations. Symptoms can manifest as unexpected results during routine testing, discrepancies between expected and actual values,…

Biosimilar residual HCP / DNA OOS during CPV trending review: CAPA strategy to restore similarity and prevent regulatory delays

Symptoms related to biosimilar residual HCP and DNA deviations during CPV reviews may manifest in several ways:Click to read the full article.

Transport time excursion during dispensing: CAPA under time-critical constraints

Identifying symptoms of transport time excursions is the first step in addressing potential deviations. Common signs may include:Click to read the full article.

Biosimilar potency OOS vs reference product after downstream resin change: CAPA strategy to restore similarity and prevent regulatory delays

The initial detection of a biosimilar potency issue typically arises in routine testing during Quality Control (QC). Symptoms indicative of a deviation from expected results may include:Click to read the…

Radiochemical purity OOS during radiopharma production: CAPA under time-critical constraints

Identifying symptoms that indicate a potential issue with radiochemical purity is the first step in managing an OOS event. Common signals include:Click to read the full article.